Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer

To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC). We collected data retrospectively from 511 consecutive patients treated with FU-based first-line...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2006, Vol.57 (1), p.91-96
Main Authors: SE HOON PARK, LEE, Jeeyun, KIM, Seonwoo, SOO MEE BANG, EUN KYUNG CHO, DONG BOK SHIN, JAE HOON LEE, SE HOON LEE, JOON OH PARK, KIM, Kihyun, WON SEOG KIM, CHUL WON JUNG, YOUNG SUK PARK, WON KI KANG, PARK, Keunchil
Format: Article
Language:English
Subjects:
Adenocarcinoma - blood
Adenocarcinoma - complications
Adenocarcinoma - drug therapy
Adenocarcinoma - mortality
Adult
Aged
Anemia - blood
Anemia - complications
Anemias. Hemoglobinopathies
Antineoplastic agents
Biological and medical sciences
Disease-Free Survival
Diseases of red blood cells
Female
Fluorouracil - administration & dosage
Fluorouracil - therapeutic use
Gastroenterology. Liver. Pancreas. Abdomen
Hematologic and hematopoietic diseases
Hemoglobins - analysis
Humans
Male
Medical sciences
Middle Aged
Multivariate Analysis
Neoplasm Metastasis
Pharmacology. Drug treatments
Retrospective Studies
Stomach Neoplasms - blood
Stomach Neoplasms - complications
Stomach Neoplasms - drug therapy
Stomach Neoplasms - mortality
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC). We collected data retrospectively from 511 consecutive patients treated with FU-based first-line chemotherapy as a routine clinical practice for AGC and followed up in two centers from 1995 to 2003. FU was given in combination with cisplatin (61%), taxanes (12%), anthracyclines (24%) and/or folinic acid (50%). Hgb values were
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-005-0027-2